Lack of adverse clopidogrel-atorvastatin clinical interaction

American Journal of Cardiology

Volumn 93, Issue 5, 2004, Pages 669-670

  Saw, Jacqueline ^a   Topol, Eric J ^a   Wienbergen, Harm ^a   Senges, Jochen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 3A4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ACUTE HEART FAILURE; ADVERSE DRUG REACTION; DATA ANALYSIS; DRUG EFFICACY; DRUG METABOLISM; HEART INFARCTION; HUMAN; NOTE; PRIORITY JOURNAL;

EID: 1442348769     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.10.002     Document Type: Letter

References (4)

1. H Wienbergen A Gitt R Shiele C Juenger T Heer C Meisenzahl P Limbourg C Bossaller J Senges Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies Am J Cardiol 92 2003 285 288
2. W.C Lau L.A Waskell P.B Watkins C.J Neer K Horowitz A.S Hopp A.R Tait D.G.M Carville K.E Guyer E.R Bates Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation Circulation 107 2002 32 37
3. S Yusuf F Zhao S Mehta S Chrolavicius G Tognoni K Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndrome without ST-segment elevation N Engl J Med 345 2001 494 502
4. J Saw S.R Steinhubl P.B Berger D.J Kereiakes V.L Serebruany D Brennan E.J Topol Lack of adverse clopidogrel–atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled, clopidogrel trial Circulation 108 2003 921 924